Scientific Journals and Books

2024

Understanding the Cytomegalovirus Cyclin-Dependent Kinase Ortholog pUL97 as a Multifaceted Regulator and an Antiviral Drug Target

Marschall M, Schutz M, Wild M, Socher E, Wangen C, Dhotre K, Rawlinson W D and Sticht H. Cells. 2024; 13 (16): doi: 10.3390/cells13161338

Inhibition of mammalian mtDNA transcription acts paradoxically to reverse diet-induced hepatosteatosis and obesity

Jiang S, Yuan T, Rosenberger F A, Mourier A, Dragano N R V, Kremer L S, Rubalcava-Gracia D, Hansen F M, Borg M, Mennuni M, Filograna R, Alsina D, Misic J, Koolmeister C, Papadea P, de Angelis M H, Ren L, Andersson O, Unger A, Bergbrede T, Di Lucrezia R, Wibom R, Zierath J R, Krook A, Giavalisco P, Mann M and Larsson N G. Nat Metab. 2024; 6 (6): 1024-1035. doi: 10.1038/s42255-024-01038-3

Fragment-Based Interrogation of the 14-3-3/TAZ Protein-Protein Interaction

Andlovic B, Valenti D, Centorrino F, Picarazzi F, Hristeva S, Hiltmann M, Wolf A, Cantrelle F X, Mori M, Landrieu I, Levy L M, Klebl B, Tzalis D, Genski T, Eickhoff J and Ottmann C. Biochemistry. 2024; 63 (17): 2196-2206. doi: 10.1021/acs.biochem.4c00248

An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity

Yu D, Wagner S, Schutz M, Jeon Y, Seo M, Kim J, Bruckner N, Kicuntod J, Tillmanns J, Wangen C, Hahn F, Kaufer B B, Neipel F, Eickhoff J, Klebl B, Nam K and Marschall M. Pharmaceutics. 2024; 16 (2): doi: 10.3390/pharmaceutics16020158

Profiling of ERBB receptors and downstream pathways reveals selectivity and hidden properties of ERBB4 antagonists

Popović L, Wintgens J P, Wu Y, Brankatschk B, Menninger S, Degenhart C, Jensen N, Wichert S P, Klebl B, Rossner M J and Wehr M C. iScience. 2024; doi: 10.1016/j.isci.2024.108839

Pyrrolopyrimidine based CSF1R inhibitors: Attempted departure from Flatland

Bjornstad F, Havik S, Aarhus T I, Mahdi I, Unger A, Habenberger P, Degenhart C, Eickhoff J, Klebl B M, Sundby E and Hoff B H. Eur J Med Chem. 2024; 265 116053. doi: 10.1016/j.ejmech.2023.116053

Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA

Teuber A, Schulz T, Fletcher B S, Gontla R, Muhlenberg T, Zischinsky M L, Niggenaber J, Weisner J, Kleinbolting S B, Lategahn J, Sievers S, Muller M P, Bauer S and Rauh D. Nat Commun. 2024; 15 (1): 63. doi: 10.1038/s41467-023-44376-8

2014

Cheminformatics at the interface of medicinal chemistry and proteomics

Koch U, Hamacher M, Nussbaumer P. Biochim Biophys Acta. 2014; 1844 (1 Pt A): 156-161. doi: 10.1016/j.bbapap.2013.05.010

Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells

Kelso T W, Baumgart K, Eickhoff J, Albert T, Antrecht C, Lemcke S, Klebl B, Meisterernst M. Mol Cell Biol. 2014; 34 (19): 3675-3688. doi: 10.1128/MCB.00595-14

Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site

Zimmermann G, Schultz-Fademrecht C, Kuchler P, Murarka S, Ismail S, Triola G, Nussbaumer P, Wittinghofer A, Waldmann H. J Med Chem. 2014; 57 (12): 5435-5448. doi: 10.1021/jm500632s

The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells

Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S, Jamieson A M, Langdon W Y, Ikeda F, Fededa J P, Cronin S J, Nitsch R, Schultz-Fademrecht C, Eickhoff J, Menninger S, Unger A, Torka R, Gruber T, Hinterleitner R, Baier G, Wolf D, Ullrich A, Klebl B M, Penninger J M. Nature. 2014; 507 (7493): 508-512. doi: 10.1038/nature12998

Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor

Albert T K, Rigault C, Eickhoff J, Baumgart K, Antrecht C, Klebl B, Mittler G, Meisterernst M. Br J Pharmacol. 2014; 171 (1): 55-68. doi: 10.1111/bph.12408

Yes, we use cookies,

Scientific Journals and Books

Archive